🇺🇸 FDA
Patent

US 11866407

Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection

granted A61KA61K31/16A61K9/0014

Quick answer

US patent 11866407 (Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/16, A61K9/0014, A61K9/0019, A61K9/0053